Klatskin Tumor: Clinical Trials

4 trials for Klatskin Tumor, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 active not recruiting, 1 recruiting, 1 terminated, 1 unknown. 4 Phase 3, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 34Active not recruiting 1, Recruiting 1, Terminated 1, Unknown 1
Phase 22Recruiting 1, Unknown 1

Follow Klatskin Tumor: new trials by email Literature Review of Klatskin Tumor trials Research Report on Klatskin Tumor

Trials (filtered) newest first · largest first

All 4 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Neoadjuvant Gemcitabine and Cisplatin in Combination With Perioperative Pembrolizumab Versus Upfront Surgery for Patients With Primary Resectable and Borderline Resectable Perihilar and Distal Cholangiocarcinoma
Pembrolizumab, Gemcitabine, Cisplatin - Extrahepatic Cholangiocarcinoma, Perihilar Cholangiocarcinoma
Phase 2 / Phase 3RecruitingAmsterdam UMC, location VUmc1502026-04-172026-08-25
Rilvegostomig + Chemotherapy as Adjuvant Therapy for Biliary Tract Cancer After Resection (ARTEMIDE-Biliary01)
Rilvegostomig, Placebo, Capecitabine - Biliary Tract Cancer
Phase 3Active not recruitingAstraZeneca7602023-12-042026-10-16
Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)
Photodynamic therapy-Photofrin, Stenting procedure, Chemotherapy regimen - Hilar Cholangiocarcinoma
Phase 3TerminatedConcordia Laboratories Inc.282014-11-122019-08-28
Percutaneous Bilateral Versus Unilateral Metal Stent for Hilar Cholangiocarcinoma
bilateral metal stent insertion, unilateral metal stent insertion - Hilar Cholangiocarcinoma
Phase 2 / Phase 3UnknownAir Force Military Medical University, China702014-07-012019-08-01

Narrower conditions

Cholangiocarcinoma (4)  ·  Bile Duct Neoplasms (2)  ·  Biliary Tract Neoplasms (1)  ·  Gallbladder Neoplasms (1)  ·  Jaundice (1)

Broader conditions

Adenocarcinoma (4)  ·  Carcinoma (4)  ·  Neoplasms (4)  ·  Neoplasms by Histologic Type (4)  ·  Neoplasms, Glandular and Epithelial (4)  ·  Bile Duct Diseases (2)  ·  Biliary Tract Diseases (2)  ·  Digestive System Diseases (2)  ·  Digestive System Neoplasms (2)  ·  Neoplasms by Site (2)  ·  Biliary Tract Neoplasms (1)  ·  Gallbladder Diseases (1)  ·  Hyperbilirubinemia (1)  ·  Pathologic Processes (1)  ·  Pathological Conditions, Signs and Symptoms (1)

Interventions

Cisplatin (3)  ·  Gemcitabine (3)  ·  Capecitabine (1)  ·  Drug Therapy (1)  ·  S 1 (combination) (1)  ·  Tegafur (1)  ·  pembrolizumab (1)

Sponsors

Air Force Military Medical University, China (1)  ·  Amsterdam UMC, location VUmc (1)  ·  AstraZeneca (1)  ·  Concordia Laboratories Inc. (1)

Countries

Canada (2)  ·  China (2)  ·  Germany (2)  ·  South Korea (2)  ·  United States (2)  ·  Australia (1)  ·  Belgium (1)  ·  Brazil (1)  ·  Denmark (1)  ·  France (1)  ·  Hong Kong (1)  ·  India (1)  ·  Italy (1)  ·  Japan (1)  ·  Netherlands (1)

Top investigators

Guohong Han, MD,Ph.D (1)  ·  Michel Kahaleh, MD (1)

NIH funding

2023 (1)